-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, under favorable factors such as favorable policies and the return of talents, domestic research and development of innovative drugs have been hot, but drug clinical trials have the characteristics of long time, difficult to recruit patients, high costs, and high risks, which have become a major part of the development of innovative drug companies.
Hinder
.
The industry pointed out that, especially in terms of clinical trial costs, clinical trials are increasingly "burning money" under multiple resonances such as the rise of investment in innovative drugs, rising patient recruitment costs, and stricter policies
.
Data show that the cost of the clinical phase usually accounts for more than 66% of the entire new drug development cost, but in recent years, the actual proportion of many innovative pharmaceutical companies has exceeded this figure
.
So, how can innovative pharmaceutical companies deal with the challenges when costs remain high? One of the directions is to cooperate with medical water seller CRO companies, which is also the practice of many innovative drug companies in recent years
.
CRO is a drug R&D outsourcing service, which can contract some non-core R&D links of pharmaceutical companies to improve efficiency, reduce costs and R&D risks
.
The data shows that the market scale of the CRO industry continues to expand in the context of the hot domestic research and development of innovative drugs
.
According to data released by Frost&Sullivan, it is estimated that by 2022, China's CRO market will reach 23.
3 billion U.
S.
dollars, with an average compound growth rate of about 20.
4% from 2018 to 2022
.
From the perspective of competition, the number of domestic clinical CRO companies has reached about 400, which is accelerating the share of the huge market blue ocean
.
In addition, some capable pharmaceutical companies also plan to build their own teams
.
For example, Fuhong Henlius recently revealed on the Global R&D Day that a large internal clinical trial project, compared to handing over to a CRO (contract research organization) enterprise, a self-built clinical trial team can The patient's cost is reduced by nearly half
.
It is understood that although the CRO industry has rich experience, the mobility of personnel in this industry is also increasing, which may lead to vicious competition
.
For example, Medicilon mentioned in the prospectus that the turnover rate of the company was 27.
03%, 33.
74%, 24.
40% and 11.
43% in each period of the reporting period, and the turnover rate was relatively high.
.
In the context of the sustained and sound development of the pharmaceutical industry and the CRO industry, the company is facing greater external pressure to tap talents, and the company faces the risk of brain drain, even high-end talent loss
.
The analysis believes that behind the high turnover of CRO industry personnel, it has a certain relationship with the increase in the number of pharmaceutical companies that have self-built CRO teams
.
At present, apart from Fuhong Henlius, innovative pharmaceutical companies with more R&D pipelines, including BeiGene and Hengrui Pharmaceuticals, have adopted the strategy of self-built CRO
.
The industry pointed out that, compared with third parties, self-built teams have higher initial investment but better controllability.
Although outsourcing organizations have more experience, they do not necessarily have advantages in quality control and cost efficiency
.
However, some people in the CRO industry believe that not all innovative drug companies are suitable for self-built teams.
For example, there are some newly established companies whose capabilities are not enough to support the expenses of self-built teams.
The clinical team may be a trend
.
However, if it develops to a larger scale, management costs will also increase.
By then, companies may continue to cooperate with CROs like multinational pharmaceutical companies
.
” On the whole, the product line is rich and scaled.
Large pharmaceutical companies may gradually establish their own clinical teams to control costs.
This also means that a competitive relationship is being formed between pharmaceutical companies and CRO companies, and the competition for talents will intensify in the future
.
Hinder
.
The industry pointed out that, especially in terms of clinical trial costs, clinical trials are increasingly "burning money" under multiple resonances such as the rise of investment in innovative drugs, rising patient recruitment costs, and stricter policies
.
Data show that the cost of the clinical phase usually accounts for more than 66% of the entire new drug development cost, but in recent years, the actual proportion of many innovative pharmaceutical companies has exceeded this figure
.
So, how can innovative pharmaceutical companies deal with the challenges when costs remain high? One of the directions is to cooperate with medical water seller CRO companies, which is also the practice of many innovative drug companies in recent years
.
CRO is a drug R&D outsourcing service, which can contract some non-core R&D links of pharmaceutical companies to improve efficiency, reduce costs and R&D risks
.
The data shows that the market scale of the CRO industry continues to expand in the context of the hot domestic research and development of innovative drugs
.
According to data released by Frost&Sullivan, it is estimated that by 2022, China's CRO market will reach 23.
3 billion U.
S.
dollars, with an average compound growth rate of about 20.
4% from 2018 to 2022
.
From the perspective of competition, the number of domestic clinical CRO companies has reached about 400, which is accelerating the share of the huge market blue ocean
.
In addition, some capable pharmaceutical companies also plan to build their own teams
.
For example, Fuhong Henlius recently revealed on the Global R&D Day that a large internal clinical trial project, compared to handing over to a CRO (contract research organization) enterprise, a self-built clinical trial team can The patient's cost is reduced by nearly half
.
It is understood that although the CRO industry has rich experience, the mobility of personnel in this industry is also increasing, which may lead to vicious competition
.
For example, Medicilon mentioned in the prospectus that the turnover rate of the company was 27.
03%, 33.
74%, 24.
40% and 11.
43% in each period of the reporting period, and the turnover rate was relatively high.
.
In the context of the sustained and sound development of the pharmaceutical industry and the CRO industry, the company is facing greater external pressure to tap talents, and the company faces the risk of brain drain, even high-end talent loss
.
The analysis believes that behind the high turnover of CRO industry personnel, it has a certain relationship with the increase in the number of pharmaceutical companies that have self-built CRO teams
.
At present, apart from Fuhong Henlius, innovative pharmaceutical companies with more R&D pipelines, including BeiGene and Hengrui Pharmaceuticals, have adopted the strategy of self-built CRO
.
The industry pointed out that, compared with third parties, self-built teams have higher initial investment but better controllability.
Although outsourcing organizations have more experience, they do not necessarily have advantages in quality control and cost efficiency
.
However, some people in the CRO industry believe that not all innovative drug companies are suitable for self-built teams.
For example, there are some newly established companies whose capabilities are not enough to support the expenses of self-built teams.
The clinical team may be a trend
.
However, if it develops to a larger scale, management costs will also increase.
By then, companies may continue to cooperate with CROs like multinational pharmaceutical companies
.
” On the whole, the product line is rich and scaled.
Large pharmaceutical companies may gradually establish their own clinical teams to control costs.
This also means that a competitive relationship is being formed between pharmaceutical companies and CRO companies, and the competition for talents will intensify in the future
.
